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Abstract
The development of human calcified aortic stenosis (AS) includes age-dependent processes that have been involved in
atherosclerosis, such as infiltration of macrophages in aortic valves, which then promote production of many pro-
inflammatory cytokines, including resistin. However, the molecular mechanisms contributing to these processes are not
established. Since Sirt1 has been shown to modulate macrophage biology and inflammation, we examined its levels in
human AS and tested its impact on resistin expression. Sirt1 mRNA (p=0.01) and protein (p,0.05) levels were reduced in
explanted valves from AS patients (n=51) compared to those from control (n=11) patients. Sirt1 mRNA levels were
negatively associated with resistin mRNA levels quantified in AS valves (p=0.02). Stimulation of Sirt1 by resveratrol or virus-
driven overexpression robustly diminished resistin mRNA and protein expression in macrophages, whereas down-regulation
of Sirt1 triggered a large increase in resistin expression. These effects were direct, as chromatin immunoprecipitation assays
showed that Sirt1 physically interacted with the resistin promoter region at an AP-1 response element. Moreover, Sirt1
blocked c-jun-induced resistin transactivation in gene reporter assays. These findings demonstrate that, in calcified AS,
levels of Sirt1 are reduced whereas those of resistin are increased within aortic valve leaflets. Our results also suggest that
this loss of Sirt1 expression alleviates its inhibition of resistin transcription in macrophages. Although the overall
contribution of this process to the underlying mechanisms for AS disease development remains unresolved, these
observations suggest that modification of Sirt1 expression and/or activity could represent a novel approach against
inflammation in AS.
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Introduction
Calcific aortic valve disease is a progressive disorder that
ranges from mild valve thickening without obstruction of blood
flow, termed aortic sclerosis, to severe calcification and
remodeling of the valve leading to impaired leaflet motion, or
aortic stenosis (AS). Despite that calcific AS has become the
most common cardiac disease in developed countries after
hypertension and coronary artery disease [1,2,3,4], the only
permanent treatment remains valve replacement surgery, and
no disease-modifying pharmacological tool is currently available.
AS increases in prevalence with advancing age, afflicting 2–3%
of the population by the age of 65 years [5].
Histopathologic and clinical data have suggested that AS is
an active disease process akin to atherosclerosis with lipoprotein
deposition and retention, chronic inflammation, recruitment of
macrophages within the valvular tissue, and active leaflet
calcification [6,7,8,9]. These physiological modifications of the
aortic valve are associated with changes in the expression of
genes implicated in the adhesion and infiltration of blood cells,
calcification, lipid retention, inflammation, and angiogenesis
[10]. However, the cellular and molecular mechanisms impli-
cated in the pathogenesis of this disease are still poorly
understood [11].
Recently, higher circulating levels of the 12 kDa hormone
resistin were associated with the severity of aortic valvular
calcification and inflammation in older patients [12]. In humans,
resistin is mostly secreted by macrophages [13]. In these cells,
resistin promotes CD36 expression and lipid accumulation
[14,15,16]. Likewise, reports linked resistin to atherosclerosis
[17,18], coronary artery calcification [18] and coronary artery
disease [19].
Sirtuin 1 (Sirt1) is a class III deacetylase that targets histones and
a variety of transcription factors and nuclear cofactors [20]. Sirt1
mediates many effects of caloric restriction in mammals [21]. In
mice, Sirt1 decreases foam cell formation [22] and promotes
eNOS-induced vasorelaxation [23]. Sirt1 was also demonstrated
to be involved in the inhibition of inflammatory pathways in
murine RAW264.7 macrophages by blunting the transcription
factor activator protein 1 (AP-1) [24,25] and reducing lipopoly-
saccharide (LPS)-induced tumor-necrosis factor (TNF)-a expres-
sion [25,26]. In human U-937 macrophages, Sirt1 also downreg-
ulates the expression of metalloproteinase 9 (MMP9) [27], the
activity of which being increased in aortic valve degeneration [28].
Since Sirt1-activating compounds have been shown to reduce
macrophage inflammatory profiles in vivo [25] and to decrease
resistin expression and secretion in adipocytes [29,30], we
hypothesized that a similar process could also take place in
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35110macrophages that infiltrate the aortic valve. Thus, we investigated
the expression levels of Sirt1 in human stenotic aortic valves
obtained from valve replacement surgery, and determined its
direct effects on the transcription of resistin in macrophages.
Methods
Ethic Statement
Aortic valves were obtained from tissue bank at Institut
Universitaire de Cardiologie et de Pneumologie de Que ´bec
(IUCPQ). IUCPQ ethic committee approved the study. Written
informed consent was received from all participants.
Tissue Collection
Stenosed valves were collected following valvular replacement
surgery and control valves were obtained following heart
transplant. Compared to control patients, those with AS were
older (69 6 2v s5 36 3 years, p , 0.0001). There was no
difference in body mass index, gender, smoking status, occurrence
of vascular disease, dyslipidemia, and diabetes between groups.
Frequency of hypertension was higher in AS patients (p=0.01);
accordingly, use of ACE inhibitors was also higher in this group
(p=0.001). Medication was otherwise similar between groups.
Valves were evaluated by a pathologist to confirm the presence
of AS or the absence of clinical signs of AS and to assign a
remodeling calcification score exactly as previously described [31].
Following their collection, valves were preserved either in RNA
later (Ambion) or PFA 1% (Acros organics). One cusp of the valve
was snap frozen in liquid nitrogen during the surgery. The frozen
cusp was then crushed in liquid nitrogen and lysis buffer B was
added (0,32 M sucrose, 10 mM TRIS, 1mM EDTA, 1mM b-
mercaptoethanol, protease inhibitor (Roche)). Tubes were incu-
bated 1 hour at 4uC with agitation then sonicated for a minute.
Supernatant was collected and proteins were quantified.
Immunoprecipitation of Sirt1 in Human Aortic Valves
40 mg of protein were precleared with protein A-sepharose
beads (GE Healthcare, Baie d’Urfe ´, QC, Canada) for 2 h at 4uC
and then centrifuged 5 min at 6000 g. Supernatants were
immunoprecipitated using 2ug of anti-Sir2(Sirt1) antibody (Milli-
pore) overnight at 4uC, and mouse IgG were used as negative
control. Immunoprecipitates were washed once with IP buffer,
twice with WB (0.25 M KCl in PBS) and then subjected to SDS–
PAGE electrophoresis on polyacrylamide gels and electrophoret-
ically transferred to polyvinylidene difluoride (PVDF) membranes.
Membranes were incubated for 1 h at room temperature in
blocking buffer [50 mM Tris–HCl pH 7.5, 150 mM NaCl, 0.02%
Tween 20, 0.04% NP40 (wash buffer) and 5% dry milk powder],
and overnight at 4uC with primary antibodies (anti-sirt1, Santa
cruz sc-15404) in wash buffer containing 5% dry milk powder.
PVDF membranes were then washed three times in wash buffer
for 8 min and incubated for 1 h with anti-rabbit immunoglobulin
G conjugated to horseradish peroxidase in wash buffer containing
5% dry milk powder at room temperature. After three washes for
8 min, the immunoreactive bands were detected by the chemilu-
minescent method. Quantification of density was computerized by
multiplying pixels x intensity using Photoshop software.
Immunohistochemistry
Sections of the valves were included in paraffin and were
mounted on slides. Tissues sections were fixed in a 60% acetone
and 40% methanol solution for 10 min at 220uC and left to dry
for 5 minutes at room temperature then washed three times with
TBS 1x. Immunohistochemistry was performed using EnVision+-
Dual link System-HRP (AEC) (Dako) following the manufacturer
instructions. Briefly, residual peroxidase activity was quenched
using Dual Endogenous Enzyme Block (Dako) for 10 minutes and
tissues samples were incubated overnight at 4uC with an anti-Sirt1
antibody (SC-15404). Washed tissues sections were incubated with
EnVision+Dual link System-HRP for 30 minutes and interactions
were revealed by adding AEC substrate for 10 minutes. Sections
were then counterstained with hematoxilin.
Immunofluorescence
Tissue sections from stenotic and normal aortic valves were
fixed in a 60% acetone and 40% methanol solution for 20 minutes
at 220uC and washed in PBS. Sections were blocked with 1%
BSA in PBS for 1 hour then incubated with primary antibodies
against Sirt1 (sc-15404, Millipore) or no antibodies overnight at
4uC. Tissue sections were washed and incubated with secondary
anti-rabbit FITC conjugated antibody (Santa-Cruz) and 1/
1000 Hoechst (bisBenzimide H33258 (Sigma)) for 1 hour. Sections
were washed and mounted using vectashield for observation.
Cell culture and Treatments
U-937 and RAW264.7 monocytes (ATCC, Manassas, USA)
were cultured in RPMI 1640 medium (GIBCO) prepared
following the manufacturer’s instructions and supplemented with
10% fetal bovine serum (Sigma), 2mM glutamine (Sigma) and
1mM sodium pyruvate (GIBCO). Cells were plated at 200 000
cells/ml and induced to differentiate with 16 ng/ml phorbol 12-
myristate 13-acetate (PMA; Fluka biochemika). Two days post-
differentiation, cells were treated (for 24 hours) with growth
medium supplemented with 1mg/ml lipopolysaccharide (Sigma)
and 50 mM resveratrol (Sigma) as indicated in figure legends.
Retroviral Infection
Viruses used in this study (pBabe or pBabe-Sirt1 for
overexpression; pSuper, pSuper-Sirt1-scrambled or pSuper-Sirt1
RNAi for downregulation) were described previously [32]. Viruses
were produced in 293T cells (ATCC, Manassas, USA) exactly as
previously described [32]. Two days later, medium was harvested,
filtered and transferred to RAW264.7 cells in the presence of
polybrene (1mg/ml). Cells were selected using puromycin (2.5mg/
ml) two days after the infection. Infected cells were grown using
complete RPMI 1640 medium described above with 2.5mg/ml
puromycin.
RNA Extraction and Quantitative Real Time PCR
RNA was isolated from cultured cells by the phenol-chloroform
methodandfromaorticvalvesusingaRNeasylipidtissueextraction
kit (Qiagen). Reverse transcription of 1 mg of RNA was performed
usingqScriptcDNAsupermix(Quanta)followingthemanufacturer’s
instructions. Quantitative real time PCR (qPCR) was performed
using SYBR Green PCR Mastermix without MgCl2 (Invitrogen)
using Rotor-Gene 3000 instrument (Corbett Research). Data were
analyzed using the standard curve method and all genes of interest
werenormalizedtothehousekeepinggeneL27forhumanvalvesand
Glyceraldehyde3-phosphatedehydrogenase(GAPDH)forthecells.
Primer sequences are: Human resistin: AGAGGCGCCTGCAG-
GATGAAAG / TGGAGGTGACGCTCTGGCAC; Human
GAPDH: CGCCAGCCGAGCCACATC / GCCAG-
CATCGCCCCACTTGA; Human Sirt1: AGTTGCCACCCA-
CACCTCTTCAT / GCCGCCTACTAATCTGCTCCTT;
Mouse resistin: GCTGAGGGTCTGGAAATGAA /
GGCCAGCCTGGACTATATGA; Mouse GAPDH: ACGG-
CAAATTCAACGGCACAGTCA / TGGGGGCATCGGCA-
Sirt1 in Aortic Stenosis
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CACCGAGGAACTACCTGAT.
ELISA Assays
After incubation of cells with indicated treatment (see figure
legend), fresh media was collected, centrifuged, and immediately
processed with an ELISA kit (DY1359 R&D systems). Proteins
were extracted from attached cells and quantified as described
above. Data are presented as pg of secreted resistin per mL of
media corrected for total protein content.
Luciferase Assays
293T cells were transfected (120 000 cells per well in 24-well
plates) using Fugene (Roche) for 12 h with 80 ng of c-jun, 150 ng
of b-galactosidase and 150 ng of Sirt1 expression plasmids
(Addgene), and co-transfected with 300 ng of a reporter plasmid
containing 3.0 kb of the human resistin promoter. The next day,
the transfection medium was removed and fresh medium was
added with or without resveratrol (20 mM). Luciferase and b-
galactosidase activities were measured 24 h later as described [33].
Results are shown as luciferase activity relative to that of b-
galactosidase.
Chromatin Immunoprecipitation
Cells were fixed in 1% formaldehyde followed by 2 washes with
1X PBS with 0.1% protease inhibitors. Nuclear pellets were
obtained using chromatin immunoprecipitation (ChIP) lysis buffer
(50 mM HEPES pH 7.5, 140 mM NaCl, Triton 1%) with 0.1%
protease inhibitors. Sonication was carried out with Sonifier cell
disrupter 185 (Branson) in ChIP lysis buffer. Immunoprecipita-
tions were performed using 200 ml of sonicated cells and 5mgo f
antibody: anti-Sirt1 (sc-15404, Santa Cruz), anti-c-Jun (sc-45,
Santa Cruz), or nonspecific rabbit IgG control (sc-2027; Santa
Cruz). DNA was isolated using a PCR purification Kit (Qiagen).
Controls were performed in each case with inputs from the
original protein sample. The sequences of the primers used for the
PCR are: AP-1 putative binding site (from 2657 to – 648 bp
upstream of resistin start codon): Forward 59-CTGGAGTG-
CAGTGCTGTGAT-39; Reverse 59 AGACTGGTCAG-
GAGGTGGTG 39; Non-specific binding: Forward 59-AAG-
CAACCCAAGTGTCCATC-39; Reverse 59
CCATCTTGCTTTCTGCCTCT 39.
Statistical Analysis
Data are expressed as mean +/- S.E.M. Statistical significance
was performed by ANOVA. A value of p, 0.05 was considered to
denote statistical significance.
Results
Reduction in SIRT1 Levels in AS
To first test whether modulation Sirt1 could contribute to AS,
gene expression levels were quantified in 11 control and 54 AS
explanted valves. Messenger RNA concentrations of interleukin-1
beta (IL-1b, 0.35 6 0.05 vs 1.47 6 0.24, p=0.04), and scavenger
receptor A (SR-A, 0.56 6 0.13 vs 1.62 6 0.20, p=0.02) were
significantly increased in AS, whereas those of SR-B1 (p=0.002)
and peroxisome proliferator-activated receptor (PPAR)g
(p=0.006) were decreased (data not shown). Sirt1 mRNA levels
were two-fold lower in AS samples than in controls (Fig. 1A,
p=0.01). As expected [12], resistin mRNA levels were two-fold
increased in AS valves compared to those in control valves (Fig. 1A,
p=0.003). Interestingly, expression levels of resistin mRNA were
inversely correlated with those of Sirt1 (p=0.02) (Fig. 1B).
Importantly, Sirt1 protein levels were also reduced in AS samples,
as evidenced by western immunoblotting (Fig. 1C), immunohis-
tochemistry (Fig. 1D) and immunofluorescence (Fig. 1D) assays.
Taken together, these findings demonstrate that AS is associated
with a robust reduction in Sirt1 expression, which was inversely
correlated with that of resistin.
Modulation of Resistin Expression by Sirt1 in
Macrophages
In humans, resistin is mostly expressed in macrophages, which
infiltrate aortic valves upon the development of AS [28]. LPS
strongly induces resistin expression in vivo and in vitro [34]. To
determine whether Sirt1 directly controls resistin expression,
human macrophages were incubated with LPS in the presence or
absence of the Sirt1 activator resveratrol. LPS treatment
diminished Sirt1 mRNA expression (p=0.01) and increased
resistin mRNA levels (p=0.002) (Figure 2A). These changes were
blunted by co-incubation with resveratrol (Fig. 2A), suggesting that
activation of Sirt1 inhibits resistin expression. Importantly,
activation of Sirt1 with resveratrol also impacted on the secreted
levels of resistin protein (Fig. 2B). To further genetically assess the
effect of Sirt1 on resistin expression, we infected macrophages with
viruses for Sirt1 overexpression or downregulation (shRNA). In
line with our findings in AS valves, downregulation of Sirt1
stimulated a 5-fold increase in resistin mRNA levels (Fig. 3B).
Despite a ten-fold Sirt1 overexpression, basal resistin mRNA levels
were not further reduced (Fig. 3B). However, overexpression of
Sirt1 completely blunted the induction of resistin following LPS
treatment (Fig. 3C). These results demonstrate that Sirt1
negatively regulates resistin expression in macrophages.
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Figure 1. Low Sirt1 levels in aortic stenosis are inversely
associated with resistin expression. A, Levels of Sirt1 and resistin
mRNA levels in aortic valves from 11 control and 51 patients with AS.
Gene mRNA was normalized to the housekeeping gene L27. B, Linear
regression between relative resistin and Sirt1 mRNA levels. Each point
represents a single patient. C, Sirt1 protein levels in aortic valves from
control and AS patients. Bar graph depicts the signal intensity relative
to that of a non-specific band. D, Sirt1 protein levels in aortic valve
tissue from control and AS patients as visualized by immunofluores-
cence (IF, top panels) and immunohistochemistry (lower panels). In IF,
FITC (green) signals were against Sirt1, whereas Hoescht (blue) signals
strain nuclei. Representative pictures are shown. In all panels, * indicates
a significant difference between groups.
doi:10.1371/journal.pone.0035110.g001
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The transcription factor AP-1 is a dimer formed by combination
of members of the Jun, Fos, or ATF families, often including c-Jun.
AP-1 controls the expression of basal and inducible genes, such as
resistin [35], of which promoter regions contain the consensus
sequence 59-TGAG/CTCA-39 also known as TPA responsive
element (TRE) [36]. Since Sirt1 binds to and represses c-Jun
transcriptional activity [37], we tested the possibility that Sirt1
inhibits resistin expression via a direct effect on its AP-1 responsive
element. Consistent with a previous study using a synthetic AP-1-
responsive promoter [37], gene reporter assays using plasmids
containing 3.0 kb of the human resistin promoter showed that
Sirt1 diminishes c-Jun-induced resistin expression (Fig. 4A).
Consistent with Fig. 2, resveratrol treatment also reduced
transactivation of the resistin promoter by c-Jun (Fig. 4A). Next,
ChIP assays were performed on U-937 macrophages treated or
not with LPS. Whereas Sirt1 was linked to an AP-1 response
element on the resistin promoter in the basal state, this interaction
was reduced in the presence of LPS (Fig. 4B). In line with this,
binding of c-Jun to the same region was increased upon LPS
treatment (Fig. 4C). Taken together, these results suggest that Sirt1
prevents c-Jun activity on the human resistin promoter, and that
this process is relieved upon an inflammatory stimulus triggered by
LPS.
Discussion
It is becoming increasingly documented that the development of
AS includes processes that have also been involved in atheroscle-
rosis, such as a pro-inflammatory profile that promotes macro-
phage infiltration in aortic valves and tissue calcification.
However, the molecular mechanisms regulating these events are
not completely understood. In this study, we show that AS in
humans is associated with low Sirt1 mRNA and protein expression
levels. We further demonstrate that Sirt1 directly inhibits resistin
promoter transactivation in cultured macrophages. Although this
remains to be experimentally tested in the context of AS in vivo,
we thus propose that the loss of Sirt1 could contribute to the
development of AS-associated inflammation by allowing an
upregulation of resistin expression in infiltrated macrophages.
Our results show that Sirt1 expression levels are lower in AS
than in control valves. The extent of this reduction in Sirt1 was not
associated with the severity of valve remodeling and calcification,
as patients with mild cusp thickening but normal structural
integrity had expression levels of Sirt1 similar to those with severe
thickening, calcified nodules and fibrosa (data not shown). These
findings suggest that the downregulation of Sirt1 occurs during the
early stages of AS development. This decrease in Sirt1 levels might
be related to the induction of AS-associated oxidative stress [38]
driven by glucose intolerance and exposure to saturated fatty
acids, as both were shown to reduce Sirt1 expression in human
monocytes [39]. Because we were able to observe resistin
expression in valves from control subjects who had no clinical
signs of AS, it is likely that low-degree macrophage infiltration
already took place. Thus, since levels of Sirt1 mRNA were affected
in AS, the reduced transactivation of the Sirt1 promoter probably
reflects a long-term change in the hormonal and cellular milieu of
the infiltrated cells. Factors contributing to this reduction remain
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Figure 2. Activation of Sirt1 inhibits resistin expression in
macrophages. A, Sirt1 and resistin mRNA levels in U937 macrophages
treated for 24 h with LPS (1 mg/mL) and resveratrol (50 mM) or their
respective vehicle. B, Secreted levels of resistin in U937 macrophages
treated as in A. Bars are representative of 3 experiments done in
triplicate. In all panels, * indicates a significant difference between
groups.
doi:10.1371/journal.pone.0035110.g002
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Figure 3. Downregulation of Sirt1 increases resistin expression
in macrophages. Sirt1 (A) and resistin (B) mRNA levels in RAW264
macrophages infected with viruses for Sirt1 overexpression (pBabe-
Sirt1) or downregulation (pSuper-Sirt1 RNAi) or their respective control
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triplicate. In all panels, * indicates a significant difference between
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which has been shown to modulate Sirt1 mRNA stability upon
oxidative stress [40].
Compared with control valves, calcified aortic valves displayed a
pro-inflammatory profile including elevated levels of resistin and
IL1b. The calcified valves also showed an mRNA expression
profile facilitating foam cell formation. Levels of SR-A were
increased and levels of PPARg and SR-B1 were decreased.
Considering that SR-A is a mediator of lipid uptake [12] and that
PPARg and SR-B1 are involved in lipid efflux [41], their
modulation increases the amount of lipid present in the
macrophages, stimulating the formation of foam cells as observed
in mineralized valves [28].
In stenotic valves, there was a negative correlation between
resistin and Sirt1 mRNA expression. To recreate the inflammatory
condition associated with AS and hyperresistinemia [42], we
treated macrophages with LPS, which was independently shown
to increase resistin [14,42,43] and decrease Sirt1 expression [26]
in these cells. In line with these results, modulation of Sirt1 by
pharmacological and genetic tools demonstrated that Sirt1 directly
impacts on resistin expression in macrophages. These findings are
consistent with the negative effect of Sirt1 activation on resistin
expression in 3T3-L1 cells [29,30]. The physical interaction
between Sirt1 and the c-jun component of AP-1 has recently been
described to negatively regulate pro-inflammatory genes in
macrophages [24,25,37]. Here, we show that Sirt1 binds to the
resistin promoter and repress the transcriptional action of c-Jun in
macrophages. Our data suggest that inflammation and oxidative
stress implicated in the development of AS downregulates Sirt1
expression in infiltrated macrophages, which in turn could thus no
longer repress AP-1, triggering resistin expression. Whereas
independent studies have shown that the same interactions
controls other pro-inflammatory genes such as TNFa in
macrophages [25], it is possible that other regions on the resistin
promoter are also involved in the repressive effect of Sirt1 [44],
especially in the presence of AS-associated lower expression of
PPARg [42,45,46].
In conclusion, our study indicates that Sirt1 levels are negatively
associated with calcified AS in humans. In cultured macrophages,
this loss allows an upregulation of resistin production. The
regulation of resistin expression by Sirt1 is direct as Sirt1 binds
the resistin promoter in the normal state. The decrease in Sirt1
levels in AS could allow an increase in c-jun transcriptional
activity, triggering transcription of the resistin gene. Thus,
modulation of Sirt1, along with that of LXR [47], TNFa [25]
and MMP-9 [1,27,37] in macrophages, could represent novel
avenues for the development of therapeutic solutions for AS,
although this obviously remains to be tested in vivo. Interestingly,
in two independent studies, levels of resistin were linked to the
severity of calcification in vascular tissues [12,18]. Moreover, a
recent report showed that Sirt1 retards calcification of vascular
smooth muscle cells in a rat model of renal failure [48]. Whether
Sirt1 also impacts on AS calcification process per se is currently
under investigation. Thus, the present study adds to the present
intensive research on specific Sirt1 agonists for the treatment of
cardiovascular diseases.
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